Study on Cep63 expression and apoptosis of thyroid papillary carcinoma cell lines TPC-1.
10.3760/cma.j.cn115330-20200610-00490
- Author:
Chen Guang LIU
1
;
Fang Qin YU
1
;
Run Sheng MA
1
;
Le Le ZHANG
1
;
Mei Qi WANG
1
;
Kai Xiang FENG
1
;
Tao WANG
1
;
De Tao YIN
1
Author Information
1. Department of Thyroid Surgery, the First Affiliated Hospital of Zhengzhou University, Key-Discipline Laboratory Clinical Medicine of Henan Province, Zhengzhou 450052, China.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
Carcinoma, Papillary/genetics*;
Cell Cycle Proteins;
Cell Line, Tumor;
Cell Movement;
Cell Proliferation;
Gene Expression Regulation, Neoplastic;
Humans;
Thyroid Cancer, Papillary/genetics*;
Thyroid Neoplasms/genetics*
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2021;56(1):62-68
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the effect of centrosomal protein Cep63 on the apoptosis of papillary thyroid carcinoma (PTC) cell lines TPC-1 and underlying mechanism. Methods: With collected PTC tissues and adjacent tissues, Cep63 expression was detected by RT-qPCR and its relationship with clinicopathological factors was analyzed. The experiment included negative control group (NC), low expression group (Cep63(-)) and overexpression group (Cep63(+)), and wild-type TPC-1 cells were transfected with Cep63 lentivirus. The efficiency of Cep63 was detected by western blot (WB) and qRT-PCR. Cell proliferation ability was detected by plate cloning experiment and MTT assay. Cell apoptotic rate was detected by flow cytometry, and expression levels of apoptosis-related proteins were detected by immunohistochemistry and WB. The t-test was used to compare the differences in the means between the two groups, the one-way analysis of variance was used to compare multiple groups, and the chi-square test was used to analyze the association between gene expression levels and pathological factors. Results: Compared with NC group, cell proliferation ability was significantly decreased in Cep63(-) group (3.18±0.07 vs. 2.14±0.09, t=8.54, P<0.01) and significantly increased in Cep63(+) group (3.18±0.07 vs. 3.58±0.10, t=3.21, P<0.05). Apoptotic rates in NC, Cep63 (-) and Cep63 (+) groups were respectively 3.03%±0.24%, 8.66%±0.44% and 1.17%±0.44%, and the flow cytometry showed that the low expression of Cep63 significantly increased the apoptosis TPC-1 cells (F=157.7, P<0.001). Bcl-2 protein expression levels of NC, Cep63 (-) and Cep63 (+) groups were respectively 1.07±0.03, 0.49±0.01 and 1.99±0.09, and BAX protein expression levels of three groups were respectively 0.64±0.02, 1.06±0.01 and 0.21±0.03. WB showed that the expression level of Bcl-2 decreased (F=183.2, P<0.001), while the expression level of BAX was significantly up-regulated (F=283.7, P<0.001). Conclusion: Cep63 may regulate the apoptotic process of TPC-1 cells through Bcl-2/BAX pathway and Cep63 may be a potential oncogene of PTC.
